Latest Content

How oncology nurses can dismantle patient myths, secure early dietitian referrals, and collaborate to optimize supportive care like vitamin D.

A JAMA Surgery study of 2.7M patients reveals decade-long increases in surgical delays, with significant racial and socioeconomic disparities.

Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.

FDA grants Humanitarian Device Exemption for OncoSil, the first Class III device delivering targeted P-32 microparticles for distal bile duct cancer.

Oncology clinical trial nurse navigator Elise Curry, RN, explains the impact of the FDA's approval of oral iberdomide for multiple myeloma.

A meta-analysis shows traditional pathology counts fail to predict which patients benefit from adding hormone therapy to postoperative radiation.

The FDA granted accelerated approval to iberdomide with daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Oncology social worker Kelly Dyckman, LCSW, shares key strategies for identifying patient distress, demystifying counseling, and managing trauma.

AMH and INHB testing can identify premenopausal patients with HR+/HER2- breast cancer who may safely avoid chemotherapy, sparing unnecessary toxicity.

Emily M. Beard, BSN, RN, OCN, CBCN, BHCN, discusses the vital role of oncology nurse navigation in addressing barriers to care and improving outcomes in cancer survivorship.

FDA approves Tudriqev-nivolumab for advanced melanoma. Learn key clinical trial data, dosing math, and safety rules for oncology nursing teams.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Dr. Michael Wong discusses clinical workflows, dosing calculations, and biosafety protocols for the newly approved Tudriqev-nivolumab regimen.